Can 18F-FDG PET/CT SUVmax values predict breast and axillary pathological complete response before neoadjuvant chemotherapy in breast cancer?
Cirugía y Cirujanos (English Edition) · 30.10.2026 · 94 (4)
DOI: 10.24875/cirue.m24000969 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cirugía y Cirujanos (English Edition), online erschienen am 30.10.2026. Verfasst von Ali Ihsan Saglam und 3 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction Breast cancer is the most common type of cancer in women. Neoadjuvant chemotherapy (NAC) has become the initial treatment for locally advanced breast cancer.1 Its use has expanded after the recommendation for using NAC to T1c-N0 patients with human epidermal growth factor receptor 2 (HER2) positive and triple negative in the 2023 NCCN guideline. […]
Zitieren
APA
Saglam, A. I., Koca, B., Yildirim, M., & Ozsoy, U. (2026). Can 18F-FDG PET/CT SUVmax values predict breast and axillary pathological complete response before neoadjuvant chemotherapy in breast cancer?. Cirugía y Cirujanos (English Edition), 94(4). https://doi.org/10.24875/cirue.m24000969
Vancouver
Saglam AI, Koca B, Yildirim M, Ozsoy U. Can 18F-FDG PET/CT SUVmax values predict breast and axillary pathological complete response before neoadjuvant chemotherapy in breast cancer?. Cirugía y Cirujanos (English Edition). 2026;94(4). doi:10.24875/cirue.m24000969
BibTeX
@article{Saglam2026,
author = {Saglam, Ali Ihsan and Koca, Bulent and Yildirim, Murat and Ozsoy, Ugur},
title = {Can 18F-FDG PET/CT SUVmax values predict breast and axillary pathological complete response before neoadjuvant chemotherapy in breast cancer?},
journal = {Cirugía y Cirujanos (English Edition)},
year = {2026},
volume = {94},
number = {4},
doi = {10.24875/cirue.m24000969}
}
EUVIMED